J. Wathen

发表

Covariate‐adjusted adaptive randomization in a sarcoma trial with multi‐stage treatments

P. Thall, J. Wathen, 2005, Statistics in medicine.

Practical Bayesian adaptive randomisation in clinical trials.

P. Thall, J. Wathen, 2007, European journal of cancer.

Accounting for patient heterogeneity in phase II clinical trials

P. Thall, E. Estey, J. Wathen, 2008, Statistics in medicine.

Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected].

P. Thall, J. Wathen, D. Reinke, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Hierarchical Bayesian approaches to phase II trials in diseases with multiple subtypes

P. Thall, J. Wathen, R. Benjamin, 2003, Statistics in medicine.

Adaptive randomized study of idarubicin and cytarabine versus troxacitabine and cytarabine versus troxacitabine and idarubicin in untreated patients 50 years or older with adverse karyotype acute myeloid leukemia.

D. Berry, E. Estey, J. Wathen, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adaptive Design: Results of 2012 Survey on Perception and Use

J. Wathen, C. Coffey, B. Gaydos, 2014, Therapeutic innovation & regulatory science.

Statistical controversies in clinical research: scientific and ethical problems with adaptive randomization in comparative clinical trials.

P. Thall, J. Wathen, P. Fox, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Some caveats for outcome adaptive randomization in clinical trials

J. Kyle Wathen, Peter F. Thall, Patricia S. Fox, 2015 .

cacy of Imatinib in Aggressive Fibromatosis: Results of a se II Multicenter Sarcoma Alliance for Research

Dafydd G. Thomas, J. Wathen, R. Maki, 2010 .

A SARC phase II multicenter trial of imatinib mesylate (IM) in patients with aggressive fibromatosis.

J. Wathen, D. Reinke, R. Maki, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Economic Evaluation of Cost and Time Required for a Platform Trial vs Conventional Trials

Jay J H Park, C. Mehta, J. Wathen, 2022, JAMA network open.

Natural history of metastatic renal cell carcinoma in patients who underwent consultation for allogeneic hematopoietic stem cell transplantation.

J. Wathen, N. Ueno, R. Champlin, 2007, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Colitis in patients with breast carcinoma treated with taxane‐based chemotherapy

G. Hortobagyi, J. Wathen, V. Valero, 2004, Cancer.

Prophylaxis of graft-versus-host disease in unrelated donor transplantation with pentostatin, tacrolimus, and mini-methotrexate: a phase I/II controlled, adaptively randomized study.

D. Berry, J. Wathen, S. Parmar, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Bayesian designs to account for patient heterogeneity in phase II clinical trials

Peter F Thall, J Kyle Wathen, P. Thall, 2008, Current opinion in oncology.

Phase II multicenter trial of imatinib in 10 histologic subtypes of sarcoma using a bayesian hierarchical statistical model.

Paul A Meyers, Laurence H Baker, J Kyle Wathen, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

P. Thall, J. Wathen, D. Reinke, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II study of sequential gemcitabine followed by docetaxel for recurrent Ewing sarcoma, osteosarcoma, or unresectable or locally recurrent chondrosarcoma: results of Sarcoma Alliance for Research Through Collaboration Study 003.

J. Wathen, D. Reinke, R. Benjamin, 2012, The oncologist.

A simulation study of outcome adaptive randomization in multi-arm clinical trials

Peter F Thall, J Kyle Wathen, P. Thall, 2017, Clinical trials.

SARC009: Phase 2 study of dasatinib in patients with previously treated, high‐grade, advanced sarcoma

Dafydd G. Thomas, J. Wathen, H. Tawbi, 2016, Cancer.

Adjuvant therapy for high‐grade, uterus‐limited leiomyosarcoma

J. Wathen, R. Maki, S. George, 2013, Cancer.

Efficacy of Imatinib in Aggressive Fibromatosis: Results of a Phase II Multicenter Sarcoma Alliance for Research through Collaboration (SARC) Trial

Dafydd G. Thomas, J. Wathen, R. Maki, 2010, Clinical Cancer Research.

Adapt ive Randomized Study of Idarubic in and Cytarabine Versus Troxaci tabine and Cytarabine Versus Troxaci tabine and Idarubic in in Untreated Pat ients 50 Years or Older With Adverse Karyotype Acute Myelo id Leukemia

D. Berry, E. Estey, J. Wathen, 2003 .

Power and Bias in Adaptively Randomized Clinical Trials Technical Report UTMDABTR-002-06

J. Kyle Wathen, John D. Cook, J. Wathen, 2006 .

Continuous Bayesian adaptive randomization based on event times with covariates

Peter F Thall, Ying Kuen Cheung, Lurdes Y T Inoue, 2006, Statistics in medicine.

Bayesian adaptive model selection for optimizing group sequential clinical trials

Peter F Thall, J Kyle Wathen, P. Thall, 2008, Statistics in medicine.

A SARC multicenter phase III study of gemcitabine (G) vs. gemcitabine and docetaxel (G+D) in patients (pts) with metastatic soft tissue sarcomas (STS).

P. Thall, J. Wathen, D. Reinke, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Best Practices in Clinical Trial Simulations for Adaptive Study Designs

J. Kyle Wathen, Cristiana Mayer, J. Wathen, 2018 .

Adjuvant therapy for high‐grade, uterus‐limited leiomyosarcoma

J. Wathen, R. Maki, S. George, 2013, Cancer.

Bayesian adaptive model selection for optimizing group sequential clinical trials

P. Thall, J. Wathen, 2008, Statistics in medicine.

A simulation study of outcome adaptive randomization in multi-arm clinical trials

P. Thall, J. Wathen, 2017, Clinical trials.